Shop By
Catalog No.
Product Name
Application
Product Information
Citations
-
Tau Inhibitor
TAU-IN-6 is a selective inhibitor of Tau protein misfolding and aggregation. It effectively inhibits the formation of stress granules comprising Tau and TIA1, making it a valuable tool in studying Tau pathology. This compound is particularly relevant for research related to Alzheimer's disease and other tauopathies. -
TTBK1/TTBK2 Inhibitor
TTBK1/2-IN-2 is a selective inhibitor of Tau tubulin kinase 1 (TTBK1) and TTBK2, exhibiting IC50 values of 384 nM and 175 nM, respectively. This compound has been shown to significantly influence ciliogenesis in human induced pluripotent stem cells (iPSCs), making it a valuable tool for studying the roles of TTBK1 and TTBK2 in cellular processes and related pathologies. Its potent inhibitory activity positions TTBK1/2-IN-2 as an important reagent for research in neurodegenerative diseases and cilia-related disorders. -
Tau-aggregation Inhibitor
Tau-aggregation-IN-3 is a potent inhibitor of Tau protein aggregation, demonstrating an EC50 value of 4.816 μM in cell-based assays. This compound is valuable for research into neurodegenerative diseases, particularly Alzheimer's disease, where Tau aggregation plays a critical role in pathogenesis. Its ability to inhibit Tau aggregation makes it a useful tool for investigating therapeutic strategies aimed at Tau-related mechanisms. -
TAU Inhibitor
TAU-IN-2 is a selective TAU inhibitor that demonstrates an EC50 value of 7.7 nM. This compound is primarily utilized in the investigation of neurodegenerative diseases, making it a valuable tool for researchers studying the role of TAU protein aggregation in conditions such as Alzheimer’s disease. Its potent inhibitory action allows for detailed exploration of TAU-related pathways and potential therapeutic interventions. -
Tau Protein Inhibitor
LDN-193665 is a potent inhibitor of Tau kinases, demonstrating significant tauopathy-modifying activity. This compound effectively reduces Tau phosphorylation and decreases Sarkosyl-insoluble Tau levels in preclinical models. Additionally, LDN-193665 has been shown to enhance cognitive function, restoring memory in animal studies and highlighting its potential application in researching tauopathies. -
TTBK1/TTBK2 Inhibitor
TTBK1/2-IN-1 is a selective inhibitor of Tau tubulin kinases TTBK1 and TTBK2, demonstrating IC50 values of 816 nM and 384 nM, respectively. This compound effectively interferes with tau phosphorylation, making it a valuable tool in research focused on tauopathies and neurodegenerative diseases. Its application can aid in understanding the role of TTBK1 and TTBK2 in cellular processes and serve as a basis for the development of therapeutics targeting tau-related pathologies. -
TTBK1 Inhibitor
TTBK1-IN-3 is a selective inhibitor of TTBK1, exhibiting a biochemical IC₅₀ of 18 nM and a cellular IC₅₀ of 259 nM. This compound is valuable for investigating the role of TTBK1 in Alzheimer's disease research. Its potency allows for detailed studies on the enzymatic pathways involved in neurodegenerative processes. -
Tau/pre-miRNA-146a Inhibitor
MG-1102 is a first-in-class dual binder targeting both monomeric tau and pre-miRNA-146a. It exhibits specific inhibition of pre-miRNA-146a, with IC50 values of 0.21 mM for double-labeled and 0.36 mM for mono-labeled forms. Additionally, MG-1102 shows a binding affinity for tau monomers, characterized by a Kd of 3.21 mM as determined by surface plasmon resonance (SPR). This compound serves as a potential multi-target-directed ligand (MTDL) for research applications related to Alzheimer’s disease. -
Tau Protein Aggregation Inhibitor
Hydromethylthionine dihydrobromide is a potent inhibitor of tau protein aggregation. By interacting with tau proteins, it effectively prevents the formation of neurotoxic aggregates, thereby reducing neurodegeneration. This compound is valuable for research involving Alzheimer's disease and other tau-related disorders, providing insights into the mechanisms of neurodegenerative processes. -
TTBK1 Inhibitor
TTBK1-IN-5 is a selective inhibitor of TTBK1, exhibiting an IC₅₀ value of 239 nM. It is designed for studies investigating the role of TTBK1 in neurodegenerative disorders, particularly Alzheimer's disease. This compound facilitates research aimed at understanding TTBK1's biological function and its potential as a therapeutic target in Alzheimer's pathology. -
TTR Inhibitor
Eplontersen sodium is a triantennary N-acetyl galactosamine (GalNAc3-7a)-conjugated antisense oligonucleotide that targets transthyretin (TTR) mRNA, effectively inhibiting the production of both variant and wild-type TTR protein. By reducing TTR levels, Eplontersen sodium plays a crucial role in addressing conditions associated with amyloid TTR (ATTR) amyloidosis, where misfolded TTR leads to the formation of amyloid fibrils affecting the heart and peripheral nerves. This compound is pivotal for research in therapeutic strategies aimed at managing hereditary and wild-type forms of amyloidosis. -
TTR Inhibitor
Inotersen is a 2'-O-methoxyethyl-modified antisense oligonucleotide targeting transthyretin (TTR) to inhibit its production. By binding to TTR mRNA, Inotersen promotes RNase H1-mediated degradation, leading to a decrease in both mutant and wild-type TTR synthesis in the liver. This reduction significantly mitigates amyloid fiber deposition, making Inotersen a valuable tool in research focused on hereditary transthyretin amyloidosis, including its related complications such as polyneuropathy and cardiomyopathy. Caution is advised, as high doses may lead to specific toxicities, including inflammation or tumor development in certain animal models. -
TTR Inhibitor
Eplontersen is a triantennary N-acetyl galactosamine (GalNAc3-7a) conjugated antisense oligonucleotide that selectively targets transthyretin (TTR) mRNA. By inhibiting the synthesis of both variant and wild-type TTR proteins, Eplontersen plays a crucial role in disrupting the misfolding of TTR, which contributes to the formation of amyloid fibrils associated with ATTR amyloidosis. This compound is valuable for research applications focused on amyloid-related diseases and exploring therapeutic strategies for TTR-related pathologies. -
WT-TTR Inhibitor
WT-TTR Inhibitor 1 is a selective inhibitor of wild-type Transthyretin (WT-TTR), demonstrating 29.05% inhibition at a concentration of 100 μM. This compound is valuable for research applications focused on amyloidogenesis and associated diseases, including familial amyloid polyneuropathy. Its demonstrated inhibitory capacity makes it a potential tool for studying the effects of WT-TTR on protein misfolding and aggregation. -
TTR Amyloid Fibril Formation Inhibitor
Dichlorophenyl-ABA is a potent inhibitor of transthyretin (TTR) amyloid fibril formation. It demonstrates the ability to significantly inhibit aggregate formation by over 80% in TTR L55P-expressing cells. This compound is valuable for research focused on amyloid-related disorders, particularly in understanding TTR's role in amyloidosis. -
TTR Inhibitor
Transthyretin-IN-3 is a benzofuran analogue that selectively inhibits transthyretin (TTR) by binding to its thyroxine binding site. This compound effectively disrupts amyloid aggregation, demonstrating an IC50 value of 5.0±0.2 μM. By preventing the dissociation of TTR tetramers into unstable monomers, Transthyretin-IN-3 shows potential in research applications related to amyloid-related diseases. -
ATTR Inhibitor
Transthyretin-IN-4 is a bivalent inhibitor targeting transthyretin (TTR) amyloidosis with a bIC50 of 0.09 µM. This compound is instrumental in researching fatal heart failure with preserved ejection fraction (HFpEF) and associated fatal arrhythmias. Its ability to modulate TTR dynamics makes it a valuable tool for investigating the pathophysiology of TTR-related diseases. -
Transthyretin Inhibitor
Transthyretin-IN-2 is a transthyretin (TTR) inhibitor that effectively targets TTR amyloidosis, demonstrating an IC50 value of 1.31 μM. This compound plays a crucial role in the study of TTR-related amyloid diseases, providing valuable insights into therapeutic approaches for managing amyloidosis. Researchers may utilize Transthyretin-IN-2 for investigations into the biochemical pathways of TTR misfolding and aggregation. -
α-synuclein Aggregation Inhibitor
SynuClean-D is an inhibitor of α-synuclein aggregation that disrupts the formation of mature amyloid fibrils, preventing their propagation. This compound has demonstrated efficacy in abolishing degeneration of dopaminergic neurons in animal models of Parkinson’s disease. SynuClean-D is valuable for studying the mechanisms of neurodegenerative disorders and developing potential therapeutic strategies. -
α-Synuclein Oligomerization Inhibitor
Minzasolmin (UCB0599; (R)-NPT200-11) is an orally bioavailable compound that functions as an α-synuclein oligomerization inhibitor. By selectively binding to misfolded α-synuclein intermediates, it disrupts aggregation and fibril formation, thereby stabilizing their conformation. This mechanism effectively reduces the formation of pathological oligomers and blocks neurotoxic signaling, contributing to decreased α-synuclein accumulation in the brain. Preclinical studies demonstrated that Minzasolmin significantly improved motor deficits and reduced neuroinflammation, as well as α-synuclein-related pathology in transgenic mouse models. -
α-Synuclein Aggregation Inhibitor
PBT434 mesylate is an orally active α-synuclein aggregation inhibitor that effectively penetrates the blood-brain barrier. This compound functions as an iron chelator, modulating transcellular iron trafficking while inhibiting iron-mediated redox activity and the aggregation of α-synuclein. PBT434 mesylate demonstrates neuroprotective effects by preventing the loss of neurons in the substantia nigra pars compacta. It holds promise for advancing research in Parkinson’s disease. -
ASYN Misfolding Inhibitor
(Rac)-Minzasolmin is an alpha-synuclein (ASYN) misfolding inhibitor that effectively penetrates the blood-brain barrier. By targeting the early stages of ASYN aggregation, (Rac)-Minzasolmin promotes the reversion of membrane-bound oligomers back to their monomeric form, thereby preventing pathological aggregation. This compound has demonstrated efficacy in reducing ASYN deposition in the retina and improving neuro-pathological indicators in two α-synuclein transgenic mouse models. It is a valuable tool for research on Parkinson's disease and dementia with Lewy bodies. -
Protein Aggregation Inhibitor
PQQ-trimethylester (PQQ-TME) is a trimethylester derivative of pyrroloquinoline quinone (PQQ) that acts as a protein aggregation inhibitor. It exhibits enhanced blood-brain barrier permeability compared to its parent compound, PQQ. PQQ-trimethylester effectively inhibits the fibrillation of α-synuclein, amyloid β1-42 (Aβ1-42), and prion proteins, making it a valuable tool for research into neurodegenerative diseases. -
α-Synuclein Aggregation Inhibitor
PBT434 is an effective α-synuclein aggregation inhibitor that crosses the blood-brain barrier. It functions as an iron chelator, modulating transcellular iron trafficking and inhibiting iron-mediated redox activity, which contributes to α-synuclein aggregation. PBT434 also protects against the loss of neurons in the substantia nigra pars compacta, making it a valuable tool for research into Parkinson's disease and related neurodegenerative disorders. -
α-Syn Aggregation Inhibitor
α-Synuclein inhibitor 10 is specifically designed to inhibit α-synuclein aggregation, demonstrating a low IC50 value of 1.08 μM. This compound exhibits strong binding affinity to the residues of α-synuclein, making it a valuable tool in the study of α-synuclein-related pathologies. It is particularly relevant for research in Parkinson's disease, providing insights into potential therapeutic approaches. -
α-Synuclein Oligomer Formation Inhibitor
α-Synuclein inhibitor 11 is a selective inhibitor of α-synuclein oligomer formation. This compound specifically targets α-synuclein without affecting tau 4R isoforms or phosphorylated tau. It serves as a valuable tool for investigating the pathological mechanisms underlying Parkinson's disease and may aid in the development of therapeutic strategies aimed at mitigating α-synuclein aggregation. -
α-Syn Aggregation Inhibitor
LETC is an orally active α-synuclein (α-Syn) aggregation inhibitor, demonstrating an EC50 of 66 nM in transfected DH60.21 neuroblastoma cells. This compound effectively crosses the blood-brain barrier, making it suitable for in vivo studies. LETC is valuable for researching synucleinopathies and understanding the mechanisms of neurodegenerative diseases associated with α-Syn aggregation. -
α-Synuclein Inhibitor
Peucedanocoumarin III acts as an inhibitor of α-synuclein and Huntington protein aggregates, promoting the clearance of nuclear and cytoplasmic β23 aggregates. This compound effectively prevents cytotoxicity associated with disease-related proteins, such as mutant Huntington proteins and α-synuclein. Peucedanocoumarin III is particularly valuable in studies focused on the mechanisms underlying Parkinson's disease and related neurodegenerative disorders. -
Α-Synuclein Inhibitor
α-Synuclein 4554W is an inhibitor of α-synuclein aggregation, specifically targeting the toxic aggregates associated with neurodegeneration. Comprising the GIVNGVKA sequence identified through intracellular library screening, this reagent effectively decreases fibril formation in α-synuclein mutants linked to Parkinson's disease. It serves as a valuable tool for research into the molecular mechanisms underlying synucleinopathies and offers potential avenues for therapeutic intervention. -
α-synuclein inhibitors
Movronersen is an antisense oligonucleotide that specifically inhibits α-synuclein expression. By targeting the mRNA of α-synuclein, this compound effectively reduces its protein levels, making it a valuable tool for research into neurodegenerative diseases such as Parkinson's disease. Movronersen can aid in the study of α-synuclein's role in pathology and the development of potential therapeutic strategies. -
α-Synuclein Inhibitor
α-Synuclein Inhibitor 9 is a selective inhibitor that targets α-synuclein, a protein implicated in neurodegenerative disorders. This compound binds to specific cavities within mature α-synuclein fibrils, effectively disrupting β-sheet formation and inhibiting the aggregation of the A53T α-synuclein variant. It demonstrates neuroprotective effects, improves brain functional connectivity, and alleviates motor dysfunction. This reagent is valuable for research focused on Parkinson's disease and related pathologies. -
Prolyl Endopeptidase Inhibitor
HUP-55 is a potent prolyl endopeptidase inhibitor with an IC50 of 5 nM. This compound significantly reduces α-synuclein dimerization in Neuro2a cells and induces autophagy in HEK293 cells. Additionally, HUP-55 effectively decreases reactive oxygen species (ROS) production in SH-SY5Y cells when administered at 10 μM. In vivo studies reveal that HUP-55 enhances motor function and reduces harmful oligomer levels of α-synuclein in the striatum in a mouse model of Parkinson’s disease, demonstrating its potential in neuroprotective research applications. -
α-Synuclein Inhibitor
α-Synuclein Inhibitor 8 is a potent inhibitor of α-Synuclein, demonstrating an IC50 value of 2.5 µM. This compound effectively inhibits both the aggregation and disaggregation of α-Synuclein fibers, reducing the formation of inclusions in neurons. Additionally, it exhibits antioxidant properties and maintains low cytotoxicity, making it a valuable tool for research into neuronal repair mechanisms and the potential treatment of Parkinson’s disease symptoms. -
α-Synuclein Inhibitor
α-Synuclein inhibitor 6 is a potent inhibitor of α-Synuclein aggregation, exhibiting an IC50 value of 1.70 μM and an inhibition ratio of 94.4% at 30 μM. This compound effectively penetrates the blood-brain barrier, making it suitable for neurodegenerative disease research. Its ability to modulate α-Synuclein aggregation provides a valuable tool for studies exploring the pathogenesis of synucleinopathies and the development of potential therapeutic strategies. -
Tau-0N4R Inhibitor
Tau-0N4R-IN-1 is an effective inhibitor of tau 0N4R oligomerization, capable of penetrating the blood-brain barrier. This compound demonstrates significant biological activity by inhibiting tau fibrosis across different isoforms, exhibiting anti-seeding effects on tau in vitro, and dose-dependently reducing α-synuclein oligomerization and inclusions. Additionally, Tau-0N4R-IN-1 is stable in mouse microsomes and has been shown to decrease amyloid-beta plaques in brain tissues from Alzheimer's disease patients, making it a valuable reagent for neurological research and drug development. -
α-Synuclein Aggregation Inhibitor
PBT434 free base is a potent α-synuclein aggregation inhibitor that effectively crosses the blood-brain barrier. This compound functions as an iron chelator, modulating transcellular iron trafficking and inhibiting iron-mediated redox activity, along with the aggregation of α-synuclein. PBT434 free base has demonstrated neuroprotective effects by preventing the loss of neurons in the substantia nigra pars compacta. It is valuable for research applications related to Parkinson's disease. -
α-Synuclein Inhibitor
α-Synuclein inhibitor 4 is a potent inhibitor of α-Synuclein (α-Syn) aggregation, exhibiting an IC50 of 0.98 μM. It demonstrates a significant inhibition ratio of 91.2% at a concentration of 30 μM. This compound is valuable in research applications focused on neurodegenerative diseases, particularly those related to amyloid formation and synucleinopathies. Its ability to penetrate the blood-brain barrier enhances its potential for in vivo studies. -
α-Syn Inhibitor
Syn-516 is an inhibitor targeting α-synuclein (α-Syn) by specifically engaging the 5' untranslated region (5'UTR) of α-Syn mRNA, resulting in an IC50 of 1.8 μM. This compound effectively inhibits the translation of α-Syn protein, demonstrating potential to alleviate motor dysfunction and colonic motility issues linked to α-Syn overexpression in murine models. Syn-516 serves as a valuable tool for research into neurodegenerative diseases, including Parkinson's disease and Lewy body dementia. -
α-synuclein Inhibitor
α-Synuclein inhibitor 15 is an inhibitor that targets the fibrillation growth of α-synuclein, with an IC50 value of 18 μM. This compound exhibits potential for investigating neurodegenerative disorders, including Parkinson's disease and Lewy body dementia. Its mechanism of action makes it a valuable tool for researchers exploring the pathophysiology of these conditions and developing therapeutic strategies. -
α-Synuclein Inhibitor
α-Synuclein-IN-17 is a selective inhibitor of α-synuclein, demonstrating an IC50 value of 9 μM. This compound exhibits significant inhibitory activity against both in vitro assembled α-synuclein fibrils and those amplified from Lewy Body Disease brain tissue. α-Synuclein-IN-17 is a valuable tool for research into Parkinson's disease and Lewy Body Disease, aiding in the study of the pathophysiological mechanisms associated with these neurodegenerative conditions. -
α-Synuclein Inhibitor
α-Synuclein-IN-18 is a selective inhibitor of α-Synuclein aggregation, targeting the conserved binding pocket on α-synuclein fibrils. This compound effectively delays the autocatalytic proliferation of α-synuclein aggregates, extending the aggregation half-life by threefold. By reducing the generation of toxic α-synuclein oligomers, α-Synuclein-IN-18 offers potential in mitigating neurotoxicity associated with neurodegenerative diseases. Its application is particularly relevant in research related to Parkinson's disease. -
α-Synuclein Inhibitor
α-Synuclein inhibitor 7 is a potent inhibitor of α-Synuclein (α-Syn) aggregation, demonstrating an IC50 value of 1.95 μM and an inhibition ratio of 85.8% at 30 μM. This compound effectively penetrates the blood-brain barrier, making it a valuable tool in the study of neurodegenerative diseases associated with α-Syn pathology. Its potential applications include investigating the mechanisms of α-Syn aggregation and exploring therapeutic strategies for conditions such as Parkinson's disease. -
α -Syn Inhibitor
α-Synuclein inhibitor 3 is an inhibitor of α-synuclein (α-Syn) aggregation. This compound demonstrates potential in combating the pathological aggregation associated with Parkinson's disease. Its application is critical for research focused on neurodegenerative disorders and understanding α-synuclein's role in synaptic function and toxicity. -
α-Synuclein Inhibitor
α-Synuclein inhibitor 5 is a potent inhibitor of α-Synuclein (α-Syn) aggregation, exhibiting an IC50 of 1.22 μM and an inhibition ratio of 94.3% at 30 μM concentration. This compound is capable of penetrating the blood-brain barrier, making it a valuable tool for research focused on neurodegenerative diseases associated with α-Syn aggregation. Its efficacy in disrupting α-Syn aggregates supports investigations into therapeutic strategies for conditions such as Parkinson's disease and related synucleinopathies. -
α-Synuclein Inhibitor
Alpinin A is a diarylheptanoid that serves as a potent inhibitor of α-synuclein aggregation. At a concentration of 10 μM, it demonstrates a significant inhibition rate of 66%. This compound is particularly valuable for research related to neurological disorders, including Parkinson’s disease, contributing to the understanding of α-synuclein's role in neurodegeneration. -
α-synuclein Inhibitor
Aerophobin-2 is a brominated compound isolated from the sponge Verongia aerophoba, acting as an α-synuclein inhibitor. This reagent effectively inhibits the aggregation of both α-synuclein (α-syn) and phosphorylated α-synuclein (pSyn), demonstrating significant neuroprotective activity. Its applications extend to studies in neurodegenerative diseases, particularly those involving synucleinopathies. -
α-synuclein Aggregation Inhibitor
α-Synuclein inhibitor 14 is a diarylheptanoid that acts as an α-synuclein aggregation inhibitor. It demonstrates a significant inhibition rate of 72.4% at a concentration of 10 μM, making it a valuable tool for studies related to neurodegenerative diseases, particularly Parkinson's disease. This compound aids in elucidating the mechanisms of α-synuclein aggregation and its impact on neuronal health. -
NF-κB Inhibitor
6-O-p-Hydroxybenzoylglutinoside is a selective NF-κB inhibitor that effectively suppresses TNF-α-activated NF-κB transcriptional activity, with an IC50 of 52.78 μM. This compound demonstrates targeted biological activity without significantly inhibiting soluble epoxide hydrolase (sEH), acetylcholinesterase (AChE), or butyrylcholinesterase (BChE). Isolated from the seeds of Catalpa bungei (Manchurian catalpa), 6-O-p-Hydroxybenzoylglutinoside is valuable for research applications focused on inflammation and signal transduction pathways. -
QPCTL Inhibitor
QP5020 is a selective QPCTL inhibitor with an IC50 value of 15 nM. This compound demonstrates notable antitumor efficacy, making it a valuable tool for cancer research. Its mechanism of action provides insights into the role of QPCTL in tumor biology and offers potential avenues for therapeutic exploration. -
Aβ Aggregation Inhibitor
Aβ-IN-5 is a potent Aβ aggregation inhibitor, demonstrating oral bioavailability. It effectively inhibits acetylcholinesterase (AChE) and butyrylcholinesterase (BuChE) with IC50 values of 21.29 μM and 1.32 μM, respectively. This compound exhibits significant neuroprotective effects while maintaining low neurotoxicity, making it a valuable tool for research on neurodegenerative diseases, particularly Alzheimer’s disease.
